Atencio, Patricia
Cabello, Alfonso
Conesa-Buendía, Francisco M.
Pérez-Tanoira, Ramón
Prieto-Pérez, Laura
Carrillo, Irene
Álvarez, Beatriz
Arboiro-Pinel, Rosa
Díaz-Curiel, Manuel
Herrero-Beaumont, Gabriel
Mediero, Aránzazu
Górgolas, Miguel
Article History
Received: 12 November 2020
Accepted: 26 May 2021
First Online: 9 June 2021
Declarations
:
: The protocol for this study was approved by the clinical research ethics committee of the Hospital Fundación Jimenez Diaz (approval code: PIC, 155–2016, approved on 20 December 2016) and is in adherence with the tenets of the Declaration of Helsinki. All patients provided signed informed consent before being included in the study.
: “Not applicable”. Our manuscript does not contain data from any individual person.
: AC has received honoraria and speakers’ fees from Gilead Sciences, MSD and ViiV. MG has received speakers’ fees from ViiV.AM has filed a patent on use of adenosine A2AR agonists to prevent prosthesis loosening (pending) and a separate patent on use of A2AR agonists and agents that increase adenosine levels to promote bone formation/regeneration. AM was supported by grants from “Instituto de Salud Carlos III” through the “Miguel Servet” Program (CP15/00053), co-funded by “Fondo Europeo de Desarrollo Regional (FEDER)”. The remaining authors have no competing interest.